HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liang, S.-L. Articles by Zhou, A. Search for Related Content PubMed PubMed Citation Articles by Liang, S.-L. Articles by Zhou, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB LOVASTATIN

Lovastatin-Induced Apoptosis in Macrophages through the Rac1/Cdc42/JNK Pathway

Clinical Chemistry Program, Department of Chemistry, Cleveland State University, Cleveland, OH 44115

Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, have been used successfully in the treatment of hypercholesterolemia for more than a decade. Statins also exhibit overall clinical benefits on cardiovascular diseases independent of their effects on lowering serum cholesterol levels. These beneficial effects of statin therapy are believed to be due, at least in part, to the anti-inflammatory and immunomodulatory roles of statins. Statin treatment reduces the levels of inflammatory markers, decreases the activation and recruitment of immune cells, and delays the progression of atherosclerosis, a chronic inflammatory disease. However, little is known about the direct impact of statins on immune cells, particularly on macrophages. We report that lovastatin, a member of the statin family, effectively induces apoptosis in macrophages. Further investigation of the molecular mechanism has revealed that Rac1 and Cdc42, the small GTPase family members, may play an important role in lovastatin-induced macrophage apoptosis. Moreover, the activation of the JNK pathway may contribute to this event. Our findings provide a better understanding of the molecular basis underlying the anti-inflammatory clinical benefits of statin therapy in cardiovascular diseases.

This article has been cited by other articles:

				A. Kromer and B. Moosmann Statin-Induced Liver Injury Involves Cross-Talk between Cholesterol and Selenoprotein Biosynthetic Pathways Mol. Pharmacol., June 1, 2009; 75(6): 1421 - 1429. [Abstract] [Full Text] [PDF]

				F. C. Cormack-Aboud, P. T. Brinkkoetter, J. W. Pippin, S. J. Shankland, and R. V. Durvasula Rosuvastatin protects against podocyte apoptosis in vitro Nephrol. Dial. Transplant., February 1, 2009; 24(2): 404 - 412. [Abstract] [Full Text] [PDF]

				A. Sassano, E. Katsoulidis, G. Antico, J. K. Altman, A. J. Redig, S. Minucci, M. S. Tallman, and L. C. Platanias Suppressive Effects of Statins on Acute Promyelocytic Leukemia Cells Cancer Res., May 1, 2007; 67(9): 4524 - 4532. [Abstract] [Full Text] [PDF]